Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H1 2017

  • ID: 4311822
  • Drug Pipelines
  • 31 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AndroScience Corp
  • Novartis AG
  • Reata Pharmaceuticals Inc
  • Vybion Inc
  • MORE
Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H1 2017, provides an overview of the Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline landscape.

Spinal and bulbar muscular atrophy or Kennedy disease is a disorder of specialized nerve cells that control muscle movement. These nerve cells originate in the spinal cord and the part of the brain that is connected to the spinal cord Symptoms include tremors, speech difficulties, muscle weakness, muscle wastage, muscle cramps and spasms and gynaecomastia. Treatment includes balanced diet and medications to reduce muscle cramps and tremors.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3 and 1 respectively.

Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AndroScience Corp
  • Novartis AG
  • Reata Pharmaceuticals Inc
  • Vybion Inc
  • MORE
  1. Introduction
  2. Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Overview
  3. Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Companies Involved in Therapeutics Development
  13. AndroScience Corp
  14. Novartis AG
  15. Reata Pharmaceuticals Inc
  16. Vybion Inc
  17. Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Drug Profiles
  18. ARM-210 - Drug Profile
  19. Product Description
  20. Mechanism Of Action
  21. R&D Progress
  22. ASC-J9/ASC-JM.X1 - Drug Profile
  23. Product Description
  24. Mechanism Of Action
  25. R&D Progress
  26. ASCJ-9 - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. BVS-857 - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. INT-41 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. RTA-901 - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. Rycal - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Dormant Projects
  47. Appendix
  48. Methodology
  49. Coverage
  50. Secondary Research
  51. Primary Research
  52. Expert Panel Validation
  53. Contact Us
  54. Disclaimer
List of Tables:
  1. Number of Products under Development for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy), H1
  2. Number of Products under Development by Companies, H1
  3. Products under Development by Companies, H1
  4. Number of Products by Stage and Target, H1
  5. Number of Products by Stage and Mechanism of Action, H1
  6. Number of Products by Stage and Route of Administration, H1
  7. Number of Products by Stage and Molecule Type, H1
  8. Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by AndroScience Corp, H1
  9. Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by Novartis AG, H1
  10. Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by Reata Pharmaceuticals Inc, H1
  11. Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by Vybion Inc, H1
  12. Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Dormant Projects, H1
List of Figures:
  1. Number of Products under Development for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AndroScience Corp
  • Novartis AG
  • Reata Pharmaceuticals Inc
  • Vybion Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll